CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) today announced that FoundationOne®, the company's flagship comprehensive genomic profile for patients with solid tumors, successfully identified clinically relevant genomic alterations in 65 percent of patients with lung adenocarcinoma whose tumors previously tested negative for alterations using multiple conventional approaches. Overall, these findings support the first-line use of comprehensive genomic profiling to detect the broadest range of genomic alterations in lung adenocarcinomas while preserving tissue. This study, conducted in collaboration with Memorial Sloan Kettering Cancer Center, was published online in Clinical Cancer Research and will appear in an upcoming print edition of the journal in a paper titled, “Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in ‘driver-negative’ lung adenocarcinomas.”
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
